
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Los Angeles - Another case of nephrogenic fibrosing dermopathy has appeared, according to Francis J. Dann, M.D., UCLA Medical Center, Los Angeles.